Skyline Venture Partners Qualified Purchaser Fund IV L P

This profile gathers the share dealings of Skyline Venture Partners Qualified Purchaser Fund IV L P across 6 companies, led by Talphera, Inc., Oruka Therapeutics, Inc. and Tetraphase Pharmaceuticals Inc. Between 25 February 2009 and 27 October 2014, the trades on record add up to 33 filings.

In open-market terms, that means 5 purchases worth €12.1M on one side and 7 sales worth €1.0M on the other. Taken together, the purchases exceed the sales by €11.1M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 1 share grant. So far in 2014, the count stands at 2 purchases and 1 sale.

In size, the median ticket on the buying side is €1.6M. Ninety days after publication, 3 purchases show a median change of +2.5%, with the price up in 67% of them. Past outcomes like these are no guarantee of what comes next.

Most recently, on 29 October 2014, the filings show a transaction in Protara Therapeutics, Inc. The last purchase on record was published on 29 October 2014, which is 4,379 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.